Abstract CT052: A phase 1/2 randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas
Year: 2023
Type: conference-abstract
Source: Cancer Research
Authors: Catherine Diefenbach, Won Seog Kim, Chan Cheah, Ajay K. Gopal, Philippe Armand, Ian Flinn, Gareth P. Gregory, Sung-Soo Yoon, Loretta Nastoupil, Jennifer Lue, Vincent Ribrag, Javier Briones, Antonio Salar-Silvestre, Anna Sureda-Balari, Matthew Ku, Hans Cruz, Paul Thaler, Ibrahim Qazi, Rachel Wei, Maya Leabman, Genevive Hernandez, Iris Sison, Elizabeth Budde
Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Samsung Medical Center, Sir Charles Gairdner Hospital, Seattle Cancer Care Alliance, University of Washington, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, Sarah Cannon, Tennessee Oncology, Monash Health, Monash University, Seoul National University, Seoul National University Hospital, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Hospital de Sant Pau, Hospital Del Mar, Institut Català d'Oncologia, The University of Melbourne, St Vincent's Hospital Melbourne, Adc Therapeutics (Switzerland), IGM Biosciences (United States), City Of Hope National Medical Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4365513123